Research Analysts Issue Forecasts for BCYC FY2025 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Bicycle Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($4.24) per share for the year. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.05) per share.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. During the same period last year, the business posted ($1.26) earnings per share. The business’s revenue for the quarter was down 50.0% on a year-over-year basis.

Several other research firms have also recently weighed in on BCYC. HC Wainwright restated a “buy” rating and set a $33.00 price objective on shares of Bicycle Therapeutics in a research report on Monday, January 13th. JMP Securities cut their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday, December 18th. Needham & Company LLC restated a “buy” rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a research report on Monday, January 13th. Stephens reissued an “equal weight” rating and set a $15.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.25.

Bicycle Therapeutics Price Performance

NASDAQ BCYC opened at $13.32 on Thursday. The company’s 50 day simple moving average is $16.92 and its two-hundred day simple moving average is $21.34. The stock has a market capitalization of $919.40 million, a PE ratio of -4.01 and a beta of 0.92. Bicycle Therapeutics has a 1 year low of $12.17 and a 1 year high of $28.67.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 2,686 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the transaction, the chief accounting officer now directly owns 32,146 shares of the company’s stock, valued at approximately $482,190. The trade was a 7.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bros. Advisors Lp Baker bought 500,000 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was bought at an average cost of $15.34 per share, with a total value of $7,670,000.00. Following the completion of the transaction, the director now owns 9,995,274 shares in the company, valued at approximately $153,327,503.16. This trade represents a 5.27 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 33,933 shares of company stock valued at $549,501 in the last 90 days. Insiders own 8.50% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Several large investors have recently bought and sold shares of the company. GAMMA Investing LLC increased its position in shares of Bicycle Therapeutics by 105.1% during the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after acquiring an additional 1,038 shares in the last quarter. L & S Advisors Inc grew its holdings in Bicycle Therapeutics by 2.4% during the third quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock valued at $1,352,000 after purchasing an additional 1,400 shares during the period. Assetmark Inc. bought a new position in shares of Bicycle Therapeutics during the 3rd quarter valued at approximately $34,000. JPMorgan Chase & Co. boosted its position in shares of Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after purchasing an additional 1,782 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after buying an additional 2,918 shares in the last quarter. 86.15% of the stock is owned by institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.